2h agoGuruFocusBULLISH 64Earnings
Why Is RHYTHM PHARMACEUTICA (RYTM) Stock Down Today?
By the Top Tier Newswire AI Desk · reviewed against 9 wire stories
RHYTHM PHARMACEUTICA (RYTM) is down -10.09% in the latest session. Our newswire has captured 9 stories on RYTM across 6 sources in the last 36 hours, with AI sentiment reading mixed (avg 55/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
The written analysis for RYTM publishes to the public page once it clears the 4-hour delay. The coverage, sentiment and session data below are already here.
RYTM by the numbers
Last: $84.01Session: -10.09%7 sessions: +2.79%Coverage: 9 stories / 6 sourcesAI sentiment: 55/100 (mixed)
The headlines behind the move
2h agoGuruFocusBULLISH 63Product/PR
Rhythm Pharmaceuticals Advances Bivamelagon Phase 3 Trials, Stock Ticker RYTM
3h agoSEC 8-KNEUTRAL 50General
RHYTHM PHARMACEUTICALS, INC. (RYTM) files 8-K
Filed: 2026-11-03 AccNo: 0001628280-26-069106 Size: 3 MB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
3h agoThe FlyNEUTRAL 52Earnings
Rhythm Pharmaceuticals sees FY26 operating expenses $360M-$380M
3h agoThe FlyBEARISH 34Earnings
Rhythm Pharmaceuticals Reports Q3 Eps 61c Consensus 74c
4h agoSeeking AlphaBULLISH 58Earnings
Rhythm Pharmaceuticals GAAP EPS of -$0.61 beats by $0.10, revenue of $92.1M beats by $7.5M
See Rhythm Pharmaceuticals' Q3 earnings: EPS beat estimates, revenue surged 79.5% year over year, and shares fell premarket.
4h agoGlobeNewswireBULLISH 63Earnings
Rhythm Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update
-- Strong U.S. launch momentum for IMCIVREE® (setmelanotide) for acquired hypothalamic obesity (HO) continues with more than 700 patient start forms as of...
13h agoStockTitanBULLISH 61Product/PR
Rhythm Pharmaceuticals and LG Chem Enter into Amendment to Bivamelagon Exclusive License Agreement
-- Amendment revised royalty structure from low-to-mid-single digits to 1% on global net sales of Rhythm MC4R agonists, including setmelanotide, bivamelagon and RM-718 --
1d agoSeeking AlphaNEUTRAL 50Earnings
Rhythm Pharmaceuticals Q3 2026 Earnings Preview
Rhythm Pharmaceuticals (RYTM) is scheduled to announce Q3 earnings results on Tuesday, November 3rd, before market open. The consensus EPS Estimate is -$0.74 (+
Frequently asked questions
Why is RYTM stock down today?
RHYTHM PHARMACEUTICA (RYTM) is down -10.09% in the latest session. Our newswire has captured 9 stories on RYTM across 6 sources in the last 36 hours, with AI sentiment reading mixed (avg 55/100). The most recent driver: "Rhythm Pharmaceuticals (RYTM) Q3 Revenue Beats Estimates, Expands U.S. and Japan Market Presence" (GuruFocus).
Is RYTM a buy right now?
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of RYTM coverage reads 55/100 over 9 stories; treat it as a research signal and do your own diligence.
How fast does this page update?
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
More moves explained today
- Why is IBTA up today (+26.82%)
- Why is STVN down today (-24.77%)
- Why is AEHR up today (+21.59%)
- Why is BVS down today (-18.40%)
- Why is GPK up today (+18.27%)
- Why is BCAX up today (+16.39%)
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on RYTM: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.